Progression of motor deficits in glioma-bearing mice

Impact of CNF1 therapy at symptomatic stages

Eleonora Vannini, Federica Maltese, Francesco Olimpico, Alessia Fabbri, Mario Costa, Matteo Caleo, Laura Baroncelli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most aggressive type of brain tumor. In this context, animal models represent excellent tools for the early detection and longitudinal mapping of neuronal dysfunction, that are critical in the preclinical validation of new therapeutic strategies. In a mouse glioma model, we developed sensitive behavioral readouts that allow early recognizing and following neurological symptoms. We injected GL261 cells into the primary motor cortex of syngenic mice and we used a battery of behavioral tests to longitudinally monitor the dysfunction induced by tumor growth. Grip strength test revealed an early onset of functional deficit associated to the glioma growth, with a significant forelimb weakness appearing 9 days after tumor inoculation. A later deficit was observed in the rotarod and in the grid walk tasks. Using this model, we found reduced tumor growth and maintenance of behavioral functions following treatment with Cytotoxic Necrotizing Factor 1 (CNF1) at a symptomatic stage. Our data provide a detailed and precise examination of how tumor growth reverberates on the behavioral functions of glioma-bearing mice, providing normative data for the study of therapeutic strategies for glioma treatment. The reduced tumor volume and robust functional sparing observed in CNF1-treated, glioma-bearing mice strengthen the notion that CNF1 delivery is a promising strategy for glioma therapy.

Original languageEnglish
Pages (from-to)23539-23550
Number of pages12
JournalOncotarget
Volume8
Issue number14
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Glioma
Growth
Neoplasms
Therapeutics
Forelimb
Motor Cortex
Hand Strength
Glioblastoma
Tumor Burden
Brain Neoplasms
cytotoxic necrotizing factor type 1
Animal Models
Maintenance

Keywords

  • Behavioral test
  • CNF1
  • Glioma
  • Motor cortex
  • Mouse model

ASJC Scopus subject areas

  • Oncology

Cite this

Vannini, E., Maltese, F., Olimpico, F., Fabbri, A., Costa, M., Caleo, M., & Baroncelli, L. (2017). Progression of motor deficits in glioma-bearing mice: Impact of CNF1 therapy at symptomatic stages. Oncotarget, 8(14), 23539-23550. https://doi.org/10.18632/oncotarget.15328

Progression of motor deficits in glioma-bearing mice : Impact of CNF1 therapy at symptomatic stages. / Vannini, Eleonora; Maltese, Federica; Olimpico, Francesco; Fabbri, Alessia; Costa, Mario; Caleo, Matteo; Baroncelli, Laura.

In: Oncotarget, Vol. 8, No. 14, 01.01.2017, p. 23539-23550.

Research output: Contribution to journalArticle

Vannini, E, Maltese, F, Olimpico, F, Fabbri, A, Costa, M, Caleo, M & Baroncelli, L 2017, 'Progression of motor deficits in glioma-bearing mice: Impact of CNF1 therapy at symptomatic stages', Oncotarget, vol. 8, no. 14, pp. 23539-23550. https://doi.org/10.18632/oncotarget.15328
Vannini, Eleonora ; Maltese, Federica ; Olimpico, Francesco ; Fabbri, Alessia ; Costa, Mario ; Caleo, Matteo ; Baroncelli, Laura. / Progression of motor deficits in glioma-bearing mice : Impact of CNF1 therapy at symptomatic stages. In: Oncotarget. 2017 ; Vol. 8, No. 14. pp. 23539-23550.
@article{edb1722350764aeab6055f357b48d030,
title = "Progression of motor deficits in glioma-bearing mice: Impact of CNF1 therapy at symptomatic stages",
abstract = "Glioblastoma (GBM) is the most aggressive type of brain tumor. In this context, animal models represent excellent tools for the early detection and longitudinal mapping of neuronal dysfunction, that are critical in the preclinical validation of new therapeutic strategies. In a mouse glioma model, we developed sensitive behavioral readouts that allow early recognizing and following neurological symptoms. We injected GL261 cells into the primary motor cortex of syngenic mice and we used a battery of behavioral tests to longitudinally monitor the dysfunction induced by tumor growth. Grip strength test revealed an early onset of functional deficit associated to the glioma growth, with a significant forelimb weakness appearing 9 days after tumor inoculation. A later deficit was observed in the rotarod and in the grid walk tasks. Using this model, we found reduced tumor growth and maintenance of behavioral functions following treatment with Cytotoxic Necrotizing Factor 1 (CNF1) at a symptomatic stage. Our data provide a detailed and precise examination of how tumor growth reverberates on the behavioral functions of glioma-bearing mice, providing normative data for the study of therapeutic strategies for glioma treatment. The reduced tumor volume and robust functional sparing observed in CNF1-treated, glioma-bearing mice strengthen the notion that CNF1 delivery is a promising strategy for glioma therapy.",
keywords = "Behavioral test, CNF1, Glioma, Motor cortex, Mouse model",
author = "Eleonora Vannini and Federica Maltese and Francesco Olimpico and Alessia Fabbri and Mario Costa and Matteo Caleo and Laura Baroncelli",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.15328",
language = "English",
volume = "8",
pages = "23539--23550",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "14",

}

TY - JOUR

T1 - Progression of motor deficits in glioma-bearing mice

T2 - Impact of CNF1 therapy at symptomatic stages

AU - Vannini, Eleonora

AU - Maltese, Federica

AU - Olimpico, Francesco

AU - Fabbri, Alessia

AU - Costa, Mario

AU - Caleo, Matteo

AU - Baroncelli, Laura

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Glioblastoma (GBM) is the most aggressive type of brain tumor. In this context, animal models represent excellent tools for the early detection and longitudinal mapping of neuronal dysfunction, that are critical in the preclinical validation of new therapeutic strategies. In a mouse glioma model, we developed sensitive behavioral readouts that allow early recognizing and following neurological symptoms. We injected GL261 cells into the primary motor cortex of syngenic mice and we used a battery of behavioral tests to longitudinally monitor the dysfunction induced by tumor growth. Grip strength test revealed an early onset of functional deficit associated to the glioma growth, with a significant forelimb weakness appearing 9 days after tumor inoculation. A later deficit was observed in the rotarod and in the grid walk tasks. Using this model, we found reduced tumor growth and maintenance of behavioral functions following treatment with Cytotoxic Necrotizing Factor 1 (CNF1) at a symptomatic stage. Our data provide a detailed and precise examination of how tumor growth reverberates on the behavioral functions of glioma-bearing mice, providing normative data for the study of therapeutic strategies for glioma treatment. The reduced tumor volume and robust functional sparing observed in CNF1-treated, glioma-bearing mice strengthen the notion that CNF1 delivery is a promising strategy for glioma therapy.

AB - Glioblastoma (GBM) is the most aggressive type of brain tumor. In this context, animal models represent excellent tools for the early detection and longitudinal mapping of neuronal dysfunction, that are critical in the preclinical validation of new therapeutic strategies. In a mouse glioma model, we developed sensitive behavioral readouts that allow early recognizing and following neurological symptoms. We injected GL261 cells into the primary motor cortex of syngenic mice and we used a battery of behavioral tests to longitudinally monitor the dysfunction induced by tumor growth. Grip strength test revealed an early onset of functional deficit associated to the glioma growth, with a significant forelimb weakness appearing 9 days after tumor inoculation. A later deficit was observed in the rotarod and in the grid walk tasks. Using this model, we found reduced tumor growth and maintenance of behavioral functions following treatment with Cytotoxic Necrotizing Factor 1 (CNF1) at a symptomatic stage. Our data provide a detailed and precise examination of how tumor growth reverberates on the behavioral functions of glioma-bearing mice, providing normative data for the study of therapeutic strategies for glioma treatment. The reduced tumor volume and robust functional sparing observed in CNF1-treated, glioma-bearing mice strengthen the notion that CNF1 delivery is a promising strategy for glioma therapy.

KW - Behavioral test

KW - CNF1

KW - Glioma

KW - Motor cortex

KW - Mouse model

UR - http://www.scopus.com/inward/record.url?scp=85016963261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016963261&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15328

DO - 10.18632/oncotarget.15328

M3 - Article

VL - 8

SP - 23539

EP - 23550

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -